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Our study demonstrates, for the first time, that lipoxin, an important anti-inflammatory 
mediator, selectively down-modulates the tumor progression stimulated by tumor-
associated macrophages, inducing the shift of macrophage profile and leading to tumor 
cell apoptosis. These unexpected results reveal important differences in M2 
macrophage subsets particularly those associated with tumors. This work suggests that 
this lipid mediator may become a new tool for reducing the development and 
progression of cancer. 
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Abbreviations used in this article: 
 
ALX/FPR2; formyl-peptide receptor type 2; 
ATL, aspirin-triggered lipoxin – 15-epi-LXA4;  
ATL-1, stable analog of ATL 
BOC-1,N-t-butoxycarbonyl-methionine-leucine-phenylalanine; 
DPI, Diphenyleneiodonium; 
EC, endothelial cells; 
FITC, fluoresceinisothiocyanate; 
GPCR, G-protein-coupled receptor; 
HMEC-1, human dermal microvascular endothelial cell line; 
iNOS, inducible nitric oxide synthase; 
LX, lipoxin; 
LXA4, one of the lipoxins derived from arachidonic acid 
Mφ, macrophages; 
 
MRC1, mannose receptor, M2 macrophage marker 
 
MV3, melanoma cell lineage; 
NO, nitric oxide;  
PE, phycoerythrin; 
Per-CP, peridinin chlorophyll 
PMA, phorbolmyristate acetate; 
ROS, reactive oxygen species;  
SPMs, specialized pro-resolving lipid mediators; 
TAM, tumor-associated macrophages;  
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Abstract 
 
In tumor microenvironments, pro-inflammatory macrophages (M1) acquire anti-
inflammatory and pro-tumor characteristics. These tumor-associated macrophages 
(TAMs), often referred to as myeloid suppressors, exhibit an M2-like profile, with low 
cytotoxic properties and a deficient modulation of NO and ROS production. Lipoxins 
(LX) and 15-epi-lipoxins are lipid mediators inducing anti-inflammatory and pro-
resolution activities in mononuclear cells, but their effects on TAMs remain to be 
elucidated. This study tested the hypothesis that ATL-1, a synthetic analogue of 15-epi-
lipoxin A4, could modulate TAM activity profile. We show that human macrophages 
(MΦ) differentiated into TAMs after incubation with conditioned medium from MV3, a 
human melanoma lineage cell. In contrast with the effects observedin the other M2 
subset and M1 profile macrophages, ATL-1 selectively decreased M2 surface markers 
in these TAM, suggesting unique behaviour of the M2d subset.  The effect was 
dependent on VEGF signaling and importantly, reproduced by the natural lipoxins, 
LXA and 15-epi-LXA4.  In parallel, ATL-1 stimulated TAM to produce NO by 
increasing the iNOS/arginase ratio and activated NADPH oxidase, triggering ROS 
production. These alterations in TAM profile induced by ATL-1 led to loss of the anti-
apoptotic effects of TAMs on melanoma cells and increased their cytotoxic properties. 
Finally, ATL-1 was found to inhibit tumor progression in vivo, which was accompanied 
by alterations in TAM profile and diminished angiogenesis. Together, the results 
suggest unexpectedly that ATL-1down-modulates tumor progression stimulated by 
TAM probably by inducing a change in the TAMs from an M2- to an M1-like profile 
thereby triggering tumor cell apoptosis. 
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1. Introduction 
 
The relationship between the inflammatory response and cancer has been 
extensively investigated.In some types of cancer, the microenvironment is similar to 
that observed in inflammatory processesand tissue repair, with the presence of 
inflammatory cells and mediators, including chemokines, cytokines, and growth factors, 
as well as changes in the processes of tissue remodeling and angiogenesis1. An early 
event in tumor progression is the recruitment of monocytes to the tumor site, where they 
differentiate into macrophages (MΦ)2,3. These cells, as important effectors of the 
inflammatory response and its resolution, can provide an immediate defense against 
neoplastic elementsbut maypromote tumor development through actionat different 
stages4-5. This paradoxical role of MΦ in cancer could be explained by their functional 
plasticity, which may result in the polarized expression of either pro- or anti-tumoral 
functions. During the acute inflammatory response, MΦ with an M1 profile acquire a 
potent cytotoxic profile, with increasing production of nitric oxide (NO) and reactive 
oxygen species (ROS), which mediate the elimination of pathogens or neoplastic cells4. 
However, evidence has shown that tumor cells can suppress these immune functions, 
primarily through down-regulation ofMΦ activity, allowing growth and spread of the 
cancer throughout the body, resulting in death of the host6-7. Tumor cells create a 
microenvironment that signals the pro-inflammatory and anti-tumoral M1 MΦ to 
acquire an M2-like profile. These MΦ, designated tumor-associated macrophages 
(TAMs), possess anti-inflammatory and pro-tumor characteristics, and, in contrast to 
M1 MΦ, exhibit low cytotoxic properties with defectiveproduction of NO and ROS, 
which allow tumor progression8-9. A number of studies have reported a positive 
correlation between high TAM density and poor prognosis in several human tumors10-12. 
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Thedual role of MΦ in both endogenous tumor defense and tumor progression suggests 
that a better understanding of the molecular and cellular mechanisms involved in 
macrophage–tumor interactions is critical to developing new tools to control cancer 
progression.  
The balance between pro- and anti-inflammatory mediators may modulate the 
outcome of the inflammatory response and consequent tumor development. Lipoxins 
(LX) are specialized pro-resolving lipid mediators (SPMs), produced by lipoxygenase 
interactions under a variety of conditions, including infection and inflammation. They 
can be produced by different biosynthetic routes in particular biological settings13-14 
and can exert selective effects on monocytes and Mφs, polarizing these cells towards 
an anti-inflammatory profile, in vitro and in vivo15-19 with potential for regulation of 
tumor growth. Although some studies reveal down-regulation of lipoxins in certain 
tumors20-21, the anti-inflammatory actions of lipoxins indicate that they play unique 
roles as mediators in there solution of inflammation and could be important targets for 
the therapeutic control of cancer, although at present little is known about their effects 
on TAM behavior in the tumor microenvironment. 
In this study, we investigated the role of lipoxins in the activity of TAMs, 
using ATL-1(15-epi-16-(para-fluoro)phenoxy-LXA4), a more stable analog of 15-
epi- lipoxinA4, an aspirin-inducible lipoxin. We show that this LXA4 analog down-
modulates the pro-tumor activity of TAM, inducing the shift from the M2 to the M1 
profile, promoting tumor cell apoptosis and controlling tumor growth in vivo. 
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2. Methods  
2.1. Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640, and 
penicillin/streptomycin/amphotericin B solution were purchased from Life 
Technologies-Invitrogen (Carlsbad, CA). SDS and type IV horseradish peroxidase 
(HRP) was purchased from Sigma (St Louis, MO). Ficoll-Hypaque and Percoll were 
purchased from Amersham Biosciences (Piscataway, NJ). Antibodies were purchased 
from ABCAM (Cambridge, MA) and Biolegend (San Diego, CA). All other reagents 
and chemicals were purchased from Sigma (St Louis, MO). ATL-1, the stable 15-epi-
LXA4 analog, was a generous gift from Dr. John F. Parkinson, Bayer Healthcare 
Pharmaceuticals.  
 
2.2. Melanoma cell culture 
MV3 human melanoma cells were obtained from the Temple University Center for 
Neurovirology and Cancer Biology (PA, USA). B16F10 murine melanoma cells were 
obtained from American Type Culture Collection (ATCC). MV3 cells were maintained 
in DMEM and B16F10 were maintained in RPMI, both enriched with 10 % fetal bovine 
serum), 3.7 g/L sodium bicarbonate, 5.2 g/L HEPES, 0.5 U/mL penicillin, and 0.5 
mg/mL streptomycin at 37°C in a humidified atmosphere of 5 % CO2. Cells were grown 
to 80-90 % confluence in 75-cm2 culture flasks and were then cultured for 3 days to 
generate conditioned medium. 
 
2.3. Murine melanoma model  
C57BL/6 mice at 6–7 wk of age were provided by the Department of Pharmacology and 
Psychobiology and all experimental procedures were performed according to guidelines 
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of the Committee on Ethical Use of Laboratory Animals of the State University of Rio 
de Janeiro, Rio de Janeiro, Brazil (CEUA/077/2012/, UERJ, Rio de Janeiro, Brazil). 
Mice were caged with free access to food and fresh water in a temperature-controlled 
room (22–24°C) on a 12-hr light/dark cycle. For the induction of tumors, mice (n = 6-8) 
were administered B16 melanoma cells (2 x105 cells/mouse suspended in 30 µl of 
saline) by the subcutaneous (s.c.) route. ATL-1 (1 µg/mouse) or ethanol (Vehicle) were 
injected intravenously 14 days after melanoma cell injection. For experimental analysis, 
mice were sacrificed on day 14 or 21 after melanoma induction and tumor mass was 
removed for histological analysis, morphometry, immunohistochemistry, and cellular 
profile. Lung and liver were analyzed to detect metastasis.  
 
2.4. Macrophage isolation and TAM differentiation 
Isolated PBMCs were obtained from EDTA (0.5 %)-treated venous blood of healthy 
volunteers by Ficoll-Hypaque density gradient, as described previously18. Cells were 
plated for 1 hr to isolate lymphocytes and monocytes were cultured for 7 days for MΦ 
maturation. To obtain TAMs, the MΦ were cultured for an additional 3 days with RPMI 
1640 medium plus conditioned medium from MV3 cultures (MV3-CM; 1:1), as 
described above.  
 
2.5. Measurement of TAM survival 
 
A modified MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
was used to quantify the effect of lipoxins on TAM survival. This method measures 
mitochondrial function as described previously18. Briefly, MΦ and TAM (2x105 
cells/well) were incubated with or without ATL-1 (10-100 nM),LXA4 (10nm) and 15-
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epi LXA4 (10nM) for 48 hr. Survival was assessed and expressed as % of live cells 
above the negative control. 
 
2.6. FACS analysis 
Fluorescence-activated cell sorting (FACS) analysis was conducted with an ACCURI 
C6 flow cytometer with CFLOW software (Becton Dickinson, Heidelberg, Germany). 
MΦ and TAMs (1x106 cells/well) cultured in 24-well plates were treated with ATL-1 
(1-100 nM), LXA4 (10nM), and 15-epi-LXA4 (10nM) for 48 hr. Following incubation, 
the cells were stained with conjugated monoclonal antibodies MRC1-phycoerythrin 
(PE), CD68-fluorescein (FITC) or CD86-PerCP-Cy5.5(Biolegend) with which they 
were incubated for 60 min at RT in the presence of blocking solution (2%bovine serum 
albumin,, 5%fetal bovine serum,  and 0.1%sodium azide). An isotype control antibody 
was used as the negative control.  
 
2.7. RNA isolation and RT-PCR 
MΦ and TAMs (3x106 cells/well) were incubated with or without ATL-1 (10 nM) for 6 
hr. Total RNA was isolated from TAMs using RNeasy Mini kits (Quiagen®,  Hilden, 
Germany) . After DNase treatment (RQ1 RNase-Free DNase), the mRNA was reverse 
transcribed using high-capacity cDNA reverse transcription kits as described 
previously22. Primers were designed based on the sequence of human IL-10 (GeneBank 
accession nº NM_000265 - IL-10: sense (5’-AATAAGGTTTCTCAAGGGGCT-3’); 
anti-sense (5’- AGAACCAAGACCCAGACATCAA-3’), GAPDH sense (5´-
CAGTCAGCCGCATCTTCTTT-3´); anti-sense (5´-AATTCCGTTGACTCCGACCTT-
3´)). PCR was performed with the following program: 1 cycle of 95°C for 5 min and 32 
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cycles of denaturation at 95°C for 45 sec, annealing at 58°C for 30 sec, and elongation 
at 72°C for 30 sec. Primers were used to validate the cDNA in each reaction). PCR 
products were separated by 2% agarose gel electrophoresis and visualized by UV 
exposure on a transilluminator. Relative band densities were determined by 
densitometric analysis using National Institutes of Health Image Software, and the 
ratios calculated. 
 
2.8. NO production 
Nitrite release by TAM was determined by the accumulation of a stable nitrite end-
product in cell-free culture supernatants using a modified Griess reaction method, as 
performed by Silva et al.(22). Briefly, TAMs (2×106 cell/mL) were incubated with 
ATL-1 (1-100 nM) for 8 hr, and the samples incubated with the Griess reagent (1 % 
sulfanilamide in 5 % phosphoric acid and 0.1 % naphtylethylenodiamine). The nitrite 
concentration was then determined as previously described22. 
 
2.9. ROS production assays 
MΦ and TAM were suspended in Hank´s balanced salt solution (HBSS) and placed in a 
white, 96-well plate (2x105 cells/well, final volume 200 µL). Following pretreatment 
with or without DPI (10 µM) or BOC-1 (10 µM) for 15 min, cells were loaded with 
Luminol (50 µM) and hydroxyphenyl-fluorescein (HPF, 10µM), and stimulated with 
ATL-1 (10 nM) or PMA (10 ng/mL), a known NADPHox inducer, as a positive control. 
Cells that remained unstimulated were considered the control group. ROS production 
was assessed as described before23. The area under the curve is expressed as the mean ± 
standard deviation (S.D.). 
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2.10. MV3 apoptosis 
MV3 apoptosis was assessed via cell cycle analysis by flow cytometry. MV3 cells were 
distributed into 24-well plates at a density of 5x105 cells/well in 10 % FBS medium. 
MΦ and TAM (1x106 cells/mL) were cultured in inserts (0.4µm) of transwell platesand 
the TAMs incubatedfor 15 min with or without DPI (10 µM), aminoguanidine (AG, 50 
µM), or PEG-catalase (30 U/mL), followed by treatment with ATL-1 (10 nM) for 15 
min. The analog and inhibitors were then removed, and TAM were co-cultured with 
MV3 cells for 72 hr. MV3cells treated with cycloheximide (5 µM) was used as the 
positive control. Thereafter, the MV3 cells were detached with 5 mM EDTA in HBSS. 
DNA content was accessed by propidiumiodide (PI) staining (50 µg/ml PI; 0.1 mg/ml 
RNase A; 0.05% Triton X-100) and analyzed by flow cytometry with Accuri C6® 
(Becton Dickinson), as previously described23.  
 
2.11. Preparation of cell extracts 
MΦ and TAM (1x106/mL) were incubated with different concentrations of ATL-1 (1-
100 nM) and then frozen in an ice bath to stop the reaction. To obtain whole cell 
extracts, cells were resuspended in lysis buffer as previously described18. The total 
protein contents of the cell extracts were determined by the Bradford method26. 
 
2.12. Immunoblotting 
The membranes were blocked with 5 % BSA in Tris-buffered saline (TBS) containing 
0.1% Tween-20, and then probed with anti-iNOS (1:500), anti-ALX/FPR2, anti-
arginase-1, anti-tubulin or anti-actin (1:1000) antibodies for 2 hr and developed as 
described previously18. Bands were visualized via an enhanced chemiluminescence 
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system (ECL, Amersham, Arlington Heights, IL). In all instances, band density values 
were corrected by subtracting the background values. 
 
2.13. Immunohistochemistry 
Twenty-one days after administration of B16F10 cells, mice were killed, the tumor 
mass removed and immersed in the fixative solution for 24 hr. It was then embedded in 
optimum cutting temperature (O.C.T., Tissue-tek®) and sliced (10 µm) perpendicular to 
the tumor base (apical-basal axis) and stained with H&E. Sections were hydrated and 
the slides washed in TBS with 0.05% Tween 20 (T-PBS, Sigma-Aldrich), blocked with 
block solution (BSA 5% in T-TBS), and immunostained with antibodies to endothelial 
cells (CD105), MΦ (F480) and TAM (MRC1), used at a 1/100 dilution in PBS/Tween 
buffer overnight at 4°C. Immunofluorescent imagesweredeveloped with antibodies 
conjugated with fluorescein or phycoerythrin and counterstained with DAPI for nuclear 
staining. An irrelevant isotype IgG was used as negative control. 
 
 
2.14.Statistical analysis 
The data are representative of different experiments and expressed as the mean ± S.D. 
The means from different treatments were compared by Student´s t-test and ANOVA, 
followed by the Bonferroni t-test for unpaired values. Statistical significance was set at 
P < 0.05. 
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3. Results 
3.1. Characterization of a TAM phenotype induced by a simulated tumor 
microenvironment in vitro 
Characteristic TAM markers are the macrophage mannose receptor (MRC1), 
and CD163, which are usually expressed on M2 cell membranes27. For induction of a 
TAM phenotype by a simulated tumor microenvironment in vitro, MΦ derived by 
maturation of peripheral blood monocytes were incubated with conditioned medium 
obtained from cultures of melanoma cells. MΦ were converted to a TAM profile 
expressing higher levels of MRC1 and CD163 than do naïve MΦ (Fig. 1A and B). 
One key feature of TAM is the high level of expression of IL-10, an 
immunosuppressive cytokine produced by tumor cells and TAMs that allows these cells 
to assume M2-related functions2. Indeed, under our experimental conditions, the TAM 
also presented high levels of IL-10 mRNA (Fig. 1C). 
LX and their analogs exert their anti-inflammatory activities via activation of 
ALX, a GPCR expressed in a variety of cellular types16. We demonstrated that TAM 
express ALX and the treatment of the cells with ATL-1 (10 nM) did not change this 
expression (Fig. 1D). Furthermore, in the presence of ATL-1, the cells maintained 
viability even after 48 hr of incubation, as demonstrated by MTT assays (Fig. 1E). 
 
3.2. ATL-1 selectively decreasesM2 marker expression by TAM 
To investigate the effects of ATL-1 on the TAM phenotype, we treated the cells 
with the analog for 72 hr. As demonstrated in Figure 2A, ATL-1 treatment decreased 
MRC1 expression to levels similar to those observed in MΦ. Furthermore, ATL-1 
inhibited IL-10 release by TAMs (Fig. 2B). The natural lipoxin, LXA4 and its aspirin-
induced analogue, 15-epi-LXA4induced similar effects to ATL-1 (Fig 2C). Instriking 
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contrast, ATL-1 had no effect on the M2 MRC1 phenotype induced by other M2 
stimuli, such as IL-4, TGF-β and VEGF, and even induced an M2 profile in M1 cells 
(Fig 2D). This suggests that TAM represent a subset of M2 macrophages which are 
selectively down-modulated by ATL-1 to an M1-like profile in vitro. A further response 
of TAM was the significant reversal of MRC1 expression by an M1 stimulus. 
 
3.3. ATL-1 effect on TAM is vascular endothelial growth factor (VEGF)-
dependent. 
In the tumor microenvironment, VEGF is the most important angiogenic factor 
and is involved in several steps of tumor progression28. Recently, our group 
demonstrated that ATL-1impairs VEGF actions both in vitro and in vivo29-30. On this 
evidence, we investigated the involvement of VEGF in the ATL-1-induced TAM 
effects. First, we found that conditioned medium from MV3 (CM-MV3) induced an M2 
profile independent of VEGF, since treatment with a neutralizing anti-VEGF antibody 
did not affect MRC1 expression on TAM (Fig. 2E). On the other hand, when M2 
polarization triggered by CM-MV3 was performed in the absence of VEGF, the ability 
of ATL-1 to alter the TAM profile was impaired (Fig.2E). These results suggest that the 
effects of ATL-1 on the TAM profile are dependent of VEGF actions. 
 
3.4. ATL-1 induces NO production by increasing theiNOS/Arginase-1 ratio in 
TAM 
In the tumor microenvironment, TAMs,in contrast to M1 cells, exhibit deficient 
production of NO due toinhibition of iNOSactivity byelevated levels of arginase-18,31. 
Figure 3B shows that TAMinduced in the present study express high levels of arginase-
1, in accord with these observations. Treatment of TAM with ATL-1 decreased 
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arginase-1 and enhanced iNOS expression, thus increasing the iNOS/arginase-1 ratio 
(Fig.3A,B and C). Corroborating these results, ATL-1 (10 nM) also induced significant 
NO production by TAM, an effect that was inhibited by BOC-1, a selective inhibitor of 
ALX/FPR2 (Fig. 3D).  
 
3.4. ATL-1 induces ROS production by TAMs 
In addition to their limited ability to produce NO8, TAM also produce low 
amounts of ROS (Fig.4A and B). After treatment with ATL-1 (10nM), TAM generated 
significantly larger amounts of ROS, an effect impaired by both BOC-1 and DPI, an 
NADPH oxidase inhibitor (Fig. 4A and B). Furthermore, ATL-1 had no effect on ROS 
production by MΦ. Additionally, we show that ATL-1,as a possible consequence of an 
increased production of ROS and NO32, induces peroxynitrite formation, an effect 
inhibited by BOC-1 (Fig 4C).  
 
3.6. ATL-1 induces MV3 apoptosis in a ROS- and NO-dependent manner 
Since the activation of NO and ROS could lead to the recovery of the cytotoxic 
properties of TAM2, we analyzed the melanoma cell cycle after 72 h of co-incubation 
with ATL-1-treated TAM. Compared to MΦ-co-cultured tumor cells, MV3 melanoma 
cells co-cultured with TAM were protected from apoptosis (Fig.5A). By contrast, the 
treatment of TAM with ATL-1 (10nM) reversed this anti-apoptotic activity of TAM on 
MV3 to levels comparable to those seen withMΦ and after an M1 stimulus (Fig. 5A). 
The incubation of tumor cells with supernatant from the ATL-1-treated TAM culture 
did not interfere with MV3 apoptosis (Fig. 5A), suggesting that the pro-apoptotic effect 
depends on the presence of the TAM. 
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To investigate the contribution of the NADPH oxidase-derived ROS to the pro-
apoptotic effects of ATL-1-treated TAM, cells were pretreated with DPI (10 µM) before 
incubation with the analog (10nM). DPI impaired ATL-1-induced MV3 apoptosis, 
indicating that the analog induces tumor cell death via activation of the NADPH oxidase 
system in TAM (Fig. 5B). 
A simultaneous increase in the production of superoxide/H2O2 and NO leads to 
potent cytotoxic properties displayed by ATL-1-stimulated TAM.To test this 
hypothesis, TAM were treated with aminoguanidine (AG,50 µM) and PEG-catalase 
(30U/mL), inhibitors of iNOS and H2O2, respectively, followed by the treatment with 
ATL-1 (10 nM). Treatment with the inhibitors completely blocked the pro-apoptotic 
effects of ATL-1, but did not potentiate the inhibitory effect of either one alone, 
suggesting that NO and H2O2 act through a common pathway (Fig. 5C). 
 
3.7. ATL-1 inhibits tumor progression in vivo. 
In view of these in vitro results, we investigated the effects of ATL-1 on tumor 
progression in a murine model in vivo. We observed that treatment with a unique dose 
of ATL-1 at the 14th day after implantation inhibits tumor growth, as observed in 
Figures 6A and B. This potent inhibition of ATL-1 was accompanied by the impaired 
angiogenic process and a decrease in the TAM marker, as shown in Figures 6C and D.  
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4. Discussion 
The relationship between the inflammatory response and cancer has been 
widely investigated. In spite of the strong evidence for their anti-inflammatory and 
pro-resolution actions, reports on the effects of lipoxins on tumor progression are 
limited. In this study, we present novel and promising data on the effects of ATL-1 on 
the behavior of TAM in the tumor microenvironment. We show that the treatment 
with ATL-1 selectively alters TAM to an M1-like profile, increasing their tumoricidal 
activity and leading to control of tumor progression in vivo. These effects emphasize 
the important role of lipoxins in modulation of the macrophage profile in the 
tumor microenvironment with consequent induction of pro-resolutive properties. As 
described before it has been demonstrated by a number of groups, including ours, that 
lipoxins and other lipid mediators can induce anti-inflammatory properties in 
mononuclear cells17-19. Indeed, Li et al, screening the effects of lipoxins on naïve 
and inflammatory monocytes and macrophages derived from the U937 cell line, 
demonstrated that LXA4 induces the M2 anti- inflammatory phenotypes
33. 
Vasconcelos et al showed that lipoxins allowed in vivo the control of macrophage 
phenotypic profile, displaying a characteristic M2 phenotype34.  
Depending on the inducing stimulus, M2 macrophages can be classified into 
four subsets35-36. M2a and M2b, activated by IL4/IL13 or immune complexes/LPS, 
respectively, exert immune regulatory functions, whereas M2c macrophages activated 
by IL-10 and TGF-β have a predominant role in suppressing immune responses and in 
promoting tissue remodeling. TAM have been reported as a novel M2 subset, called 
M2d, that are apt to promote tumor growth, tissue remodeling, angiogenesis, and 
suppression of adaptive immunity1,3,4,36. Although there is a paucity of evidence for 
the lipoxin effects on macrophages present in the conditions of the tumor 
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microenvironment, we have demonstrated for the first time that the stable derivative of 
aspirin-induced LXA4, ATL-1, alters the TAM profile to an M1-like phenotype. In 
contrast, we observed that ATL-1 induces an M2 profile in Mφs activated by LPS and 
IFNɣ that exhibit an M1 profile, and maintains M2 polarization in Mφ treated with 
IL4, a classical M2 stimulus, indicating a specificity of t h e  LX effect on TAM 
polarization.  
We demonstrated that the effect of lipoxins on TAM polarization appears to be 
dependent on VEGF released in the tumor microenvironment. Our data strongly 
suggest that prior signaling triggered by VEGF during the differentiation of Mφs in 
TAMs would be an essential step for the specific effect of lipoxins on TAM. We 
propose that VEGF, in synergy with other factors released into the tumor 
microenvironment, such as TGF-β, VEGF, IL4 and IL10, may trigger distinct 
intracellular signaling, which induces the unique M2-like profile, which differentiates 
TAM from other M2-phenotypes. Corroborating this hypothesis, Linde et al showed 
that, beyond its chemotactic effect, VEGF induces the production of IL- 4 by a 
macrophage subset and of IL10 by tumor cells, so potentiating M2 polarization30. 
The recruitment, maturation, and differentiation of infiltrating leukocytes in 
tumors are dependent upon the local conditions in the tumor microenvironment, 
which play a central role in the activation of specific pathways expressed by TAM37. 
In this study, we observed that ATL-1, besides decreasing the expression of the 
mannose receptor MRC1, a characteristic surface antigen marker of TAM27, also 
drastically inhibited IL-10 gene expression. IL-10, a known anti-inflammatory and 
immunosuppressive cytokine, reported to be present in the microenvironment of 
different tumors, inhibits the expression of pro-inflammatory mediators, including 
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IL-12, inducible cyclooxygenase, and nitric oxide synthase, by phagocytic cells7,38-
40. This inhibitory effects of the ATL analog contrast clearly with other reports 
showing that lipoxins can induce IL-10 synthesis by macrophages in a non-tumor 
environment41. Moreover, this inhibition of IL-10 expression by ATL-1 suggests that 
the alteration in macrophage profile could facilitate the restoration of their potent 
cytotoxic activities, thereby increasing NO and ROS production. 
Indeed,  we  demonstrated  that  ATL-1,  in  changing  the  TAM  
phenotype, increases  the  production  of  NO  and  induces  ROS  generation  by  
activating  the NADPHox  system. These pro-oxidative effects triggered in TAM 
contrast, again, with those obtained in other Mφ phenotypes, where inhibitory effects 
of lipoxins and other ALX/FPR2 agonists on reactive species production were 
demonstrated4 2 - 4 4 . Corroborating the hypothesis of a selective effect of ATL-1 on 
TAM, we demonstrated that it had no effect on ROS production by peripheral blood-
derived Mφs. The NO production is consequence of a balance between iNOS and 
arginase-1 activity9. The arginase pathway limits arginine availability for iNOS action 
and NO synthesis. Interestingly, NO production by TAM triggered by ATL-1 seems to 
be more closely related to a decline in arginase-1 expression than to an 
augmentation in iNOS expression, resulting in an increase in the iNOS/arginase-1 
ratio.  
Several studies have demonstrated that malignant cells are able to grow 
indefinitely because of unregulated proliferative capacity and acquired resistance to 
apoptosis, allowing these cells to become invasive and metastatic45-46. Alterations in 
the TAM profile and the recovery of the cytotoxic properties of Mφs have been 
proposed as part of an efficient strategy to control tumor progression9. Our data 
indicate that ATL-1, by triggering ROS and NO production, enables TAM to induce 
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apoptosis of MV3 melanoma cells. Inhibition of either NADPH oxidase or iNOS 
systems alone impaired  the  pro-apoptotic  effect  of  ATL-1-stimulated  TAMs  
on  the  tumor  cells, suggesting that both reactive species, ROS and NO, share a 
common pathway. An increased production of superoxide/H2O2 and NO leads to the 
production of the highly cytotoxic mediator peroxynitrite32 consistent with our 
observation that ATL-1 induces peroxynitrite production by TAM. Conceivably this 
metabolite could be the main factor responsible for the potent cytotoxic properties 
displayed by ATL-1- stimulated TAM. The data would appear to indicate the 
involvement of different M2 subsets under the same umbrella of the M2 markers used 
to define the M2 phenotype in this study. 
Tumor cells need to avoid apoptosis, which is also induced by limited supplies 
of oxygen, nutrients, and growth factors47. ATL-1, in addition to its ability to alter 
TAMs to a tumor pro-apoptotic phenotype, also inhibited human endothelial cell 
tubulogenesis stimulated by TAM in vitro (Supplemental Figure S1). Furthermore, the 
treatment with ATL-1 decreased, in parallel with M2 cell population, angiogenic 
markers in the tumor microenvironment, in vivo. The data corroborate early studies 
that suggested ATL-1 as a potent inhibitor of angiogenesis by down-regulating 
VEGFR activation, and inhibiting migration and proliferation of endothelial cells31-32.  
Taken together, our data support the idea that the shift in macrophage profile can also 
contribute to the anti-angiogenic effects of ATL-1 in vivo . 
The production of ATL by aspirin in vivo results from the inhibition of COX-2 
through its acetylation14. Non-steroidal anti-inflammatory drugs (NSAIDs), including 
aspirin, were reported to impair tumor progression through the suppression of 
proliferation, the induction of apoptosis, and the inhibition of the invasiveness of 
neoplastic cells48-49. Interestingly, Claria et al showed that ATL was produced by 
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aspirin-activated neutrophils co-cultured with tumor cells50, and proposed that lipoxins 
may have a function in the control of cancer by affecting leukocyte activity. 
Corroborating this suggestion, we demonstrate for the first time that lipoxins, by 
inducing a shift from the M2-like (TAM) to the M1-like profile, promote inhibitory 
effects on tumor cell proliferation and survival, leading to tumor cell apoptosis and 
control of tumor progression in vivo. This work highlights an important role for lipoxins 
in tumor progression and suggests that these lipid mediators may become new targets 
for reducing the development and progression of cancer.  
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Figures Legends 
Figure 1 - Characterization of a TAM phenotype induced by simulated tumor 
microenvironment in vitro. A-B) MΦwere cultured with or without conditioned 
medium from melanoma cells for 72hr to TAM differentiation. Expression of the M2 
markers, MRC1(A) and CD163 (B) was assessed by flow cytometry using the anti-
MRC1-PE and CD163-APC antibodies. CD68-FITC and CD80-PerCP-Cy5 were used 
as the MΦ marker. The figure is representative of three experiments performed 
separately. C)MΦ and TAM (3x106 cells) were treated with ATL-1 (10 nM) for 6 hours. 
Cells were lysed in TRIZOL® and IL-10 gene expression was investigated by RT-PCR 
analysis. GAPDH was used as load control. Figure is representative of three 
experiments performed separately. D) MΦ and TAM (1x106 cells) were treated with 
ATL-1 (10 nM) for 48 hr. ALX/FPR2 expression was investigated by Western blot. The 
figure is representative of three experiments performed separately. E) MΦ and TAM 
(2x105 cells) were treated with ATL-1 (10-100 nM) for 48 hr. Cell viability was 
assessed by the MTT assay. Results are expressed as the mean ± S.D of three 
independent experiments. 
 
Figure 2 - ATL-1 selectively decreases M2 markers expression by TAMs.A)MΦ and 
TAMs (1x106 cells) were incubated with or without ATL-1 (1-100nM) for 72 hours. 
MRC1 expression was assessed by flow cytometry using the antibody anti-MRC1-
PE.The results are expressed as the mean ± S.D of three independent experiments.*, P < 
0.05 when compared to MΦ; **, P < 0.05 when compared to TAMs. B) MΦ and TAM 
(1x106 cells) were treated with ATL-1 (10 nM) for 24 hours. IL-10 release was assessed 
by ELISA using an anti-IL10 antibody. The results are expressed as the mean ± S.D of 
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three independent experiments.*, P < 0.05 when compared to TAM alone. C) MΦ and 
TAM (1x106 cells) were incubated with or without ATL-1(10nM), 15-epi-LXA4(10nM), 
LXA4 (10nM) and in the latter case, with M1 stimulus (LPS1µg/mL + IFNγ 40ng/mL) 
for 72 hr. MRC1 expression was assessed by flow cytometry using the antibody anti-
MRC1-PE.The results are expressed as the mean ± S.D of three independent 
experiments.*, P < 0.05 when compared to control MΦ; **, P < 0.05 when compared to 
TAM. D) MΦ (1x106 cells) were incubated with medium alone, MV3 conditioned 
medium (TAM), M1 stimulus (LPS1µg /mL + IFNγ 40ng/mL), M2 stimuli: IL-4 
(100ng/mL), TGF-β (10ng/mL) or VEGF (10ng/mL) for 3 days. After washing cells 
were then incubated in the presence or absence of ATL-1 (10 nM) for 72 hr. MRC1 
expression was assessed by flow cytometry using the anti-MRC1-PE antibody. The 
results are expressed as the mean ± S.E. of three independent experiments.*, P < 0.05 
when compared to control MΦ; **, P < 0.05 when compared to TAM. #, P < 0.05 when 
compared to M1. E) MΦ were incubated with MV3 conditioned-medium (CM-MV3) in 
the presence or absence of monoclonal anti-VEGF (0.1µg/mL) for 72 hours. The results 
of treating MΦ and TAMs (1x106 cells) with or without ATL-1 (10 nM) for 48 hr are 
shown for comparison. MRC1 expression was assessed by flow cytometry using the 
anti-MRC1-PE antibody. The results are expressed as the mean ± S.D of three 
independent experiments.*, P < 0.05 when compared to untreated MΦ; **,P< 0.05 
when compared to untreated TAM. 
 
Figure 3. ATL-1 induces NO production by increasing the iNOS/Arginase-1 ratio 
in TAMs. A-C) TAMs (1x106 cells) were incubated with ATL-1 (10-100 nM) for 2 hr. 
The cells were lysed in a specific buffer and analysed by SDS-PAGE. A) iNOS/actin 
ratio. B) Arginase-1/actin ratio. C) iNOS/Arginase-1 ratio. Protein expression was 
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evaluated by immunoblotting with specific antibodies. The results are expressed as the 
mean ± S.D. The data shown are representative of three independent experiments. *, P< 
0.05 compared with MΦ.**, P< 0.05 compared with TAMs alone. D) TAM (2x105/mL) 
were cultured in 96-well plates, pretreated with BOC-1 (10 µM), and treated with ATL-
1 (1-100 nM) for 8 hr. NO production was assessed by the Griess Reaction and 
analyzed on an Envision® plate reader, as described in the Methods. *, P< 0.05 when 
compared with TAMs alone. **, P< 0.05 when compared with TAMs treated with 
ATL-1. 
 
Figure 4.ATL-1 induces ROS production by TAMs. A) MΦ and TAMs (2 x 105/mL) 
were pre-treated with BOC-1 (10 µM) or DPI (10 µM) and then incubated with or 
without ATL-1 (10 nM) for 1 hr in the presence of luminol as a chemiluminogenic 
probe (50 µM). BOC-1 alone had no effect. PMA was used as a positive control. The 
figure is representative of 4 experiments. B) ROS production. Mean ± S.D. of the area 
under the curve. C) MΦ and TAMs (2 x 105/mL) were pre-treated with BOC-1 (10 µM) 
and then incubated with or without ATL-1 (10 nM) for 30 min in the presence of HPF 
as a chemiluminogenic probe (10µM). The results are expressed as the mean ± S.D of 
four independent experiments. *, P < 0.05 compared with MΦ. **, P < 0.05 compared 
to cells treated with ATL-1. 
 
Figure 5.ATL-1 induces MV3 apoptosis in a ROS and NO dependent manner. A) 
MΦ and TAM (1x106 cells) were cultured in transwellsand the TAM treated with or 
without ATL-1 (10 nM)or an M1 stimulus (LPS1µg /mL + IFNγ 40ng/mL) for 15 min. 
The analog was then removed, and the cells were co-cultured with MV3 for 72 hours. 
MV3 apoptosis was assessed by cell cycle analysis via flow cytometry. Cycloheximide 
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(CHX)-treated MV3 cells were used as the positive control. SN TAM+ATL-1; 
supernatant from the ATL-1-treated TAM. Dashed line,  MV3 cells alone. B-C) MΦ 
and TAM (1x106 cells) cultured in transwells were pretreated for 15 min as shown in 
the Figure with or without B)DPI (10 µM); or C) aminoguanidine (AG, 50 µM) and 
polyethyleneglycol-catalase (PEG-Cat) (30 U/mL), followed by treatment with ATL-1 
(10 nM) for 15 min. The analog and inhibitors were then removed, and the cells  co-
cultured with MV3 cells 72 hr. MV3 apoptosis was assessed by cell cycle analysis via 
flow cytometry.The results are expressed as the mean ± S.D of three independent 
experiments.*, P < 0.05 when compared to MΦ; **, P < 0.05 when compared to TAMs; 
#, P < 0.05 when compared to TAM plus ATL-1. 
 
Figure 6. ATL-1 inhibits tumor progression in vivo. Groups of 6-8 mice were 
inoculated with B16F10 tumor cells. The tumor mass was removed from the animals on 
the 14th and 21st day after B16F10 injection. ATL-1 (1 µg/mouse) or ethanol (vehicle 
alone) was injected on day 14, as described in Methods section 2.3. A) Tumor volume 
and B) weight were analyzed. The excised tumors were immunostained with antibodies 
for: C) blood vessels (CD105-PE) and D) whole macrophage (F4/80-FITC) or M2 
macrophages (MRC1-PE). DAPI was used for nuclear staining shown in the upper 
right-hand square. An isotype IgG was used as negative control. Pictures are 
representative of each group. *, P< 0.05.**, P< 0.01. 
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